JP2004516283A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516283A5
JP2004516283A5 JP2002551540A JP2002551540A JP2004516283A5 JP 2004516283 A5 JP2004516283 A5 JP 2004516283A5 JP 2002551540 A JP2002551540 A JP 2002551540A JP 2002551540 A JP2002551540 A JP 2002551540A JP 2004516283 A5 JP2004516283 A5 JP 2004516283A5
Authority
JP
Japan
Prior art keywords
amino
oxo
fluorophenyl
chloro
buten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002551540A
Other languages
English (en)
Japanese (ja)
Other versions
JP3827641B2 (ja
JP2004516283A (ja
Filing date
Publication date
Priority claimed from DE10063435A external-priority patent/DE10063435A1/de
Application filed filed Critical
Publication of JP2004516283A publication Critical patent/JP2004516283A/ja
Publication of JP2004516283A5 publication Critical patent/JP2004516283A5/ja
Application granted granted Critical
Publication of JP3827641B2 publication Critical patent/JP3827641B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002551540A 2000-12-20 2001-12-12 キナゾリン誘導体、その医薬組成物、使用及び製法 Expired - Lifetime JP3827641B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (de) 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PCT/EP2001/014569 WO2002050043A1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
JP2004516283A JP2004516283A (ja) 2004-06-03
JP2004516283A5 true JP2004516283A5 (OSRAM) 2006-03-02
JP3827641B2 JP3827641B2 (ja) 2006-09-27

Family

ID=7667887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002551540A Expired - Lifetime JP3827641B2 (ja) 2000-12-20 2001-12-12 キナゾリン誘導体、その医薬組成物、使用及び製法

Country Status (39)

Country Link
EP (2) EP2112140A1 (OSRAM)
JP (1) JP3827641B2 (OSRAM)
KR (1) KR100852102B1 (OSRAM)
CN (1) CN1277822C (OSRAM)
AR (1) AR040524A1 (OSRAM)
AT (1) ATE430136T1 (OSRAM)
AU (2) AU2002219174B2 (OSRAM)
BE (1) BE2014C009I2 (OSRAM)
BG (1) BG66139B1 (OSRAM)
BR (1) BRPI0116266B8 (OSRAM)
CA (1) CA2432428C (OSRAM)
CY (2) CY1109290T1 (OSRAM)
CZ (1) CZ302721B6 (OSRAM)
DE (2) DE10063435A1 (OSRAM)
DK (1) DK1345910T3 (OSRAM)
EA (1) EA006317B1 (OSRAM)
EE (1) EE05244B1 (OSRAM)
ES (1) ES2326617T3 (OSRAM)
FR (1) FR14C0009I2 (OSRAM)
HR (1) HRP20030504B1 (OSRAM)
HU (2) HU228874B1 (OSRAM)
IL (2) IL156277A0 (OSRAM)
LT (1) LTC1345910I2 (OSRAM)
LU (1) LU92370I2 (OSRAM)
ME (1) ME02777B (OSRAM)
MX (1) MXPA03005559A (OSRAM)
MY (1) MY136086A (OSRAM)
NO (3) NO325672B1 (OSRAM)
NZ (1) NZ526918A (OSRAM)
PL (1) PL214798B1 (OSRAM)
PT (1) PT1345910E (OSRAM)
RS (1) RS50860B (OSRAM)
SI (1) SI1345910T1 (OSRAM)
SK (1) SK287573B6 (OSRAM)
TW (1) TWI295992B (OSRAM)
UA (1) UA74614C2 (OSRAM)
UY (1) UY27078A1 (OSRAM)
WO (1) WO2002050043A1 (OSRAM)
ZA (1) ZA200304141B (OSRAM)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP45508A (en) 1999-06-21 2011-02-10 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10307165A1 (de) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
KR100832593B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
EP1948180B1 (en) 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
EP3173084B1 (en) * 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
PL1981863T3 (pl) 2006-01-26 2013-03-29 Boehringer Ingelheim Int Sposób wytwarzania pochodnych chinazoliny podstawionych przez ugrupowanie aminokrotonyloaminowe
SI2068880T1 (sl) * 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
KR101703941B1 (ko) * 2008-11-10 2017-02-07 내셔날 헬스 리서치 인스티튜트 티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물
WO2010081817A1 (en) 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US20120136004A1 (en) * 2009-05-14 2012-05-31 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
EP2647375A1 (en) 2009-05-14 2013-10-09 Boehringer Ingelheim International Gmbh Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases
HRP20191005T1 (hr) 2009-07-06 2019-08-23 Boehringer Ingelheim International Gmbh Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
WO2011084796A2 (en) * 2009-12-21 2011-07-14 Qiang Zhang Novel quinazoline derivatives
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
JP2013536244A (ja) 2010-08-26 2013-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ阻害剤の投与方法
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
KR20220031732A (ko) 2011-03-04 2022-03-11 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
EP2753616A1 (en) 2011-10-06 2014-07-16 Ratiopharm GmbH Crystalline forms of afatinib di-maleate
CN103073539B (zh) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
ME02648B (me) 2012-01-17 2017-06-20 Astellas Pharma Inc Jedinjenje pirazin karboksamida
CN103772380A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
WO2014118197A1 (en) 2013-02-01 2014-08-07 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
SI2986304T1 (sl) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
WO2014180271A1 (zh) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103254182A (zh) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 一种阿法替尼的制备方法
CN103242303B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 阿法替尼的制备方法
WO2014183560A1 (zh) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN103755688B (zh) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 一种阿法替尼化合物的制备方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015103456A1 (en) 2014-01-02 2015-07-09 Teva Pharmaceuticals International Gmbh Crystalline forms of afatinib di-maleate
CN105315263B (zh) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 阿法替尼中间体的合成方法
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (zh) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
US10231973B2 (en) 2015-03-20 2019-03-19 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of quinazoline derivative and method for preparing the same
CN105175400B (zh) * 2015-09-29 2018-04-10 河北神威药业有限公司 一种阿法替尼中间体的制备方法
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (zh) * 2016-10-21 2019-05-24 河北神威药业有限公司 一种制备阿法替尼的中间体及其对映异构体的检测方法
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11708335B2 (en) 2017-12-18 2023-07-25 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
CN110437163A (zh) * 2018-05-03 2019-11-12 斯特恩格林公司 作为酪氨酸激酶抑制剂的嘧啶类化合物
CA3113241A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN109265449B (zh) * 2018-11-07 2021-11-23 沈阳工业大学 Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN109824657A (zh) * 2019-03-26 2019-05-31 石药集团中奇制药技术（石家庄）有限公司 一种二马来酸阿法替尼新晶型及其制备方法和应用
KR20220047810A (ko) 2019-08-15 2022-04-19 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 알키닐 퀴나졸린 화합물
CN110590682A (zh) * 2019-10-14 2019-12-20 重庆医科大学 一种制备阿法替尼杂质的方法以及制备的杂质
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN121135654A (zh) * 2021-09-30 2025-12-16 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
CA3249080A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
IL317733A (en) 2022-06-27 2025-02-01 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001595B1 (ru) * 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
WO2000051991A1 (en) * 1999-02-27 2000-09-08 Boehringer Ingelheim Pharma Kg 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES
DE19911366A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19908567A1 (de) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
MEP45508A (en) * 1999-06-21 2011-02-10 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
JP4939716B2 (ja) * 2000-04-08 2012-05-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法

Similar Documents

Publication Publication Date Title
JP2004516283A5 (OSRAM)
IL156277A (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
JP2004517048A5 (OSRAM)
ZA200300991B (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof.
CA2541928A1 (en) Method for the production of amino crotonyl compounds
JP4009681B2 (ja) 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
CN110292580B (zh) 用于制备抗癌剂al3818、其结晶形式和其盐的方法
DK1731511T3 (en) Bicyclic heterocyclic structures, pharmaceutical compositions containing these compounds, their use and process for their preparation
CA2472293C (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
AU2010276460A1 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
JPWO1997017329A1 (ja) 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
CA2845380A1 (en) Crystalline forms of cabazitaxel
CN101163698B (zh) 制备5-（4-[4-（5-氰基-3-吲哚基）-丁基]-1-哌嗪基）-苯并呋喃-2-甲酰胺的方法
CA2599328C (en) Quinazoline derivative having tyrosine kinase inhibitory activity
CN103382183B (zh) 4-苯胺喹唑啉衍生物多晶型物及其制法和应用
KR101151642B1 (ko) 5ｈｔ4-길항제로서의 아미노설포닐 치환된4-(아미노메틸)-피페리딘 벤즈아미드
CN105669567A (zh) 一种酪氨酸激酶抑制剂及其制备方法和用途
EP2655364A1 (en) A process for the preparation of lapatinib and its ditosylate salt
CN108822095B (zh) 苯并[h]色烯类化合物及其作为AcrB外排泵抑制剂在抗菌中的应用
JP6594333B2 (ja) Ｈｘ塩の形態の（ｅ）−４−ｎ，ｎ−ジアルキルアミノクロトン酸の製造方法、およびｅｇｆｒチロシンキナーゼ阻害剤の合成のためのその使用
CN111217821B (zh) 系列二噁烷并喹唑啉衍生物的制备方法
US8993579B2 (en) Polymorphic forms of Lapatinib ditosylate and processes for their preparation
CN112209875B (zh) 一种6-氨基-4-(4-苯氧基苯乙基氨基)喹唑啉衍生物及其制备方法和应用
CN119613455A (zh) 一种新型微管蛋白与金属蛋白酶的双靶点抑制剂及其制备方法和应用
AU2011349026A1 (en) A process for the preparation of Lapatinib and its ditosylate salt